Peter Marks – Director, Center for Biologics Evaluation and Research (CBER), US FDA

Dr Peter Marks MD, PhD, director of the Center for Biologics Evaluation and Research (CBER) at the US Food and Drug Administration (FDA), highlights the Center’s contributions related to the regulatory science behind vaccine development, including vaccines to prevent COVID-19; the Center’s efforts to facilitate the advancement of the field of gene therapy; as well as his commitment to following the science and remaining steadfast to the truth.  
We need to try and make sure that we are following the science [on COVID-19 vaccines] very closely, and refrain from getting lost in all the noise that is out there in the current environment
Become a PharmaBoardroom Member for free to access this content
Join the 35,000+ pharmaceutical professionals who already subscribe to PharmaBoardroom
Already a member? Sign In

Related Interviews

Latest Report